Literature DB >> 21359843

Genomics of the NF-κB signaling pathway: hypothesized role in ovarian cancer.

Kristin L White1, David N Rider, Kimberly R Kalli, Keith L Knutson, Gail P Jarvik, Ellen L Goode.   

Abstract

OBJECTIVE: We sought to review evidence linking nuclear factor-kappa B (NF-κB) to ovarian cancer and to identify genetic variants involved in NF-κB signaling.
METHODS: PubMed was reviewed to inform on ovarian cancer biology and NF-κB signaling and to identify key genes. Public linkage disequilibrium (LD) data were analyzed to identify informative inherited variants (tagSNPs) using ldSelect.
RESULTS: We identified 319 key NF-κB genes including five NF-κB subunits, 167 activating genes, and 55 inhibiting genes. We found that the 1000 Genomes Project was the most informative LD source for most genes (92.8%), and we identified 13,027 LD bins (r (2) ≥ 0.9, minor allele frequency ≥ 0.05) and 1,018 putative-functional variants worthy of investigation. We also report that reliance on a commonly used genome-wide SNP array and genotype imputation with HapMap Phase II data provides data on only 74% of the common inherited NF-κB SNPs of interest.
CONCLUSIONS: Compelling evidence suggests that NF-κB plays a critical role in ovarian cancer, yet inherited variation in these genes has not been thoroughly assessed in relation to disease risk or outcome. We present a collection of variants in key genes and suggest creation of a custom genotyping array as an optimal approach.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21359843      PMCID: PMC3119514          DOI: 10.1007/s10552-011-9745-4

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  154 in total

1.  Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines.

Authors:  R P Negus; G W Stamp; J Hadley; F R Balkwill
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1).

Authors:  Linda Vermeulen; Gert De Wilde; Petra Van Damme; Wim Vanden Berghe; Guy Haegeman
Journal:  EMBO J       Date:  2003-03-17       Impact factor: 11.598

3.  IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development.

Authors:  Y Cao; G Bonizzi; T N Seagroves; F R Greten; R Johnson; E V Schmidt; M Karin
Journal:  Cell       Date:  2001-12-14       Impact factor: 41.582

Review 4.  NF-kappaB signaling: a tale of two pathways in skeletal myogenesis.

Authors:  Nadine Bakkar; Denis C Guttridge
Journal:  Physiol Rev       Date:  2010-04       Impact factor: 37.312

Review 5.  Nuclear factor-kappaB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia.

Authors:  Håkon Reikvam; Astrid Marta Olsnes; Bjørn Tore Gjertsen; Elisabeth Ersvar; Øystein Bruserud
Journal:  Crit Rev Oncog       Date:  2009

Review 6.  Role of genetic polymorphisms and ovarian cancer susceptibility.

Authors:  Peter A Fasching; Simon Gayther; Leigh Pearce; Joellen M Schildkraut; Ellen Goode; Falk Thiel; Georgia Chenevix-Trench; Jenny Chang-Claude; Shan Wang-Gohrke; Susan Ramus; Paul Pharoah; Andrew Berchuck
Journal:  Mol Oncol       Date:  2009-02-04       Impact factor: 6.603

7.  Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells.

Authors:  Amina Zoubeidi; Susan Ettinger; Eliana Beraldi; Boris Hadaschik; Anousheh Zardan; Leo W J Klomp; Colleen C Nelson; Paul S Rennie; Martin E Gleave
Journal:  Mol Cancer Res       Date:  2010-01-12       Impact factor: 5.852

8.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

9.  Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades.

Authors:  Jill S Barnholtz-Sloan; Ann G Schwartz; Faisal Qureshi; Suzanne Jacques; John Malone; Adnan R Munkarah
Journal:  Am J Obstet Gynecol       Date:  2003-10       Impact factor: 8.661

10.  Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis.

Authors:  C L Pearce; A H Wu; S A Gayther; A E Bale; P A Beck; J Beesley; S Chanock; D W Cramer; R DiCioccio; R Edwards; Z S Fredericksen; M Garcia-Closas; E L Goode; A C Green; L C Hartmann; E Hogdall; S K Kjaer; J Lissowska; V McGuire; F Modugno; K Moysich; R B Ness; S J Ramus; H A Risch; T A Sellers; H Song; D O Stram; K L Terry; P M Webb; D C Whiteman; A S Whittemore; W Zheng; P D P Pharoah; G Chenevix-Trench; M C Pike; J Schildkraut; A Berchuck
Journal:  Br J Cancer       Date:  2008-01-22       Impact factor: 7.640

View more
  16 in total

1.  Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.

Authors:  Britton Trabert; Ligia Pinto; Patricia Hartge; Troy Kemp; Amanda Black; Mark E Sherman; Louise A Brinton; Ruth M Pfeiffer; Meredith S Shiels; Anil K Chaturvedi; Allan Hildesheim; Nicolas Wentzensen
Journal:  Gynecol Oncol       Date:  2014-08-23       Impact factor: 5.482

2.  Analysis of wntless (WLS) expression in gastric, ovarian, and breast cancers reveals a strong association with HER2 overexpression.

Authors:  Jonathan Stewart; Jacqueline James; Glenn W McCluggage; Stephen McQuaid; Kenneth Arthur; David Boyle; Paul Mullan; Darragh McArt; Benedict Yan; Gareth Irwin; D Paul Harkin; Lei Zhengdeng; Chee-Wee Ong; Jia Yu; David M Virshup; Manuel Salto-Tellez
Journal:  Mod Pathol       Date:  2014-09-26       Impact factor: 7.842

3.  FGF18 as a prognostic and therapeutic biomarker in ovarian cancer.

Authors:  Wei Wei; Samuel C Mok; Esther Oliva; Sung-hoon Kim; Gayatry Mohapatra; Michael J Birrer
Journal:  J Clin Invest       Date:  2013-09-09       Impact factor: 14.808

4.  Effects of probucol on cell proliferation in human ovarian cancer cells.

Authors:  Lea-Yea Chuang; Jinn-Yuh Guh; Yi-Ling Ye; Ying-Ho Lee; Jau-Shyang Huang
Journal:  Toxicol Res (Camb)       Date:  2015-12-10       Impact factor: 3.524

5.  Targeting cancer cell metabolism: The combination of metformin and 2-Deoxyglucose regulates apoptosis in ovarian cancer cells via p38 MAPK/JNK signaling pathway.

Authors:  Jie Zhu; Ya Zheng; Haiyan Zhang; Hong Sun
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

6.  Symbiotic prodrugs (SymProDs) dual targeting of NFkappaB and CDK.

Authors:  Sandeep Rana; Smit Kour; Yogesh A Sonawane; Caroline M Robb; Jacob I Contreras; Smitha Kizhake; Muhammad Zahid; Adam R Karpf; Amarnath Natarajan
Journal:  Chem Biol Drug Des       Date:  2020-04-22       Impact factor: 2.817

7.  Ovarian cancer: emerging molecular-targeted therapies.

Authors:  Carole Sourbier
Journal:  Biologics       Date:  2012-06-20

8.  Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.

Authors:  Donavon Hiss
Journal:  J Oncol       Date:  2012-02-06       Impact factor: 4.375

9.  Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10.

Authors:  Bridget Charbonneau; Matthew S Block; William R Bamlet; Robert A Vierkant; Kimberly R Kalli; Zachary Fogarty; David N Rider; Thomas A Sellers; Shelley S Tworoger; Elizabeth Poole; Harvey A Risch; Helga B Salvesen; Lambertus A Kiemeney; Laura Baglietto; Graham G Giles; Gianluca Severi; Britton Trabert; Nicolas Wentzensen; Georgia Chenevix-Trench; Alice S Whittemore; Weiva Sieh; Jenny Chang-Claude; Elisa V Bandera; Irene Orlow; Kathryn Terry; Marc T Goodman; Pamela J Thompson; Linda S Cook; Mary Anne Rossing; Roberta B Ness; Steven A Narod; Jolanta Kupryjanczyk; Karen Lu; Ralf Butzow; Thilo Dörk; Tanja Pejovic; Ian Campbell; Nhu D Le; Clareann H Bunker; Natalia Bogdanova; Ingo B Runnebaum; Diana Eccles; James Paul; Anna H Wu; Simon A Gayther; Estrid Hogdall; Florian Heitz; Stanley B Kaye; Beth Y Karlan; Hoda Anton-Culver; Jacek Gronwald; Claus K Hogdall; Diether Lambrechts; Peter A Fasching; Usha Menon; Joellen Schildkraut; Celeste Leigh Pearce; Douglas A Levine; Susanne Kruger Kjaer; Daniel Cramer; James M Flanagan; Catherine M Phelan; Robert Brown; Leon F A G Massuger; Honglin Song; Jennifer A Doherty; Camilla Krakstad; Dong Liang; Kunle Odunsi; Andrew Berchuck; Allan Jensen; Jan Lubinski; Heli Nevanlinna; Yukie T Bean; Galina Lurie; Argyrios Ziogas; Christine Walsh; Evelyn Despierre; Louise Brinton; Alexander Hein; Anja Rudolph; Agnieszka Dansonka-Mieszkowska; Sara H Olson; Philipp Harter; Jonathan Tyrer; Allison F Vitonis; Angela Brooks-Wilson; Katja K Aben; Malcolm C Pike; Susan J Ramus; Elisabeth Wik; Cezary Cybulski; Jie Lin; Lara Sucheston; Robert Edwards; Valerie McGuire; Jenny Lester; Andreas du Bois; Lene Lundvall; Shan Wang-Gohrke; Lukasz M Szafron; Sandrina Lambrechts; Hannah Yang; Matthias W Beckmann; Liisa M Pelttari; Anne M Van Altena; David van den Berg; Mari K Halle; Aleksandra Gentry-Maharaj; Ira Schwaab; Urmila Chandran; Janusz Menkiszak; Arif B Ekici; Lynne R Wilkens; Arto Leminen; Francesmary Modugno; Grace Friel; Joseph H Rothstein; Ignace Vergote; Montserrat Garcia-Closas; Michelle A T Hildebrandt; Piotr Sobiczewski; Linda E Kelemen; Paul D P Pharoah; Kirsten Moysich; Keith L Knutson; Julie M Cunningham; Brooke L Fridley; Ellen L Goode
Journal:  Cancer Res       Date:  2013-11-22       Impact factor: 12.701

10.  Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer.

Authors:  Matthew S Block; Bridget Charbonneau; Robert A Vierkant; Zachary Fogarty; William R Bamlet; Paul D P Pharoah; Mary Anne Rossing; Daniel Cramer; Celeste Leigh Pearce; Joellen Schildkraut; Usha Menon; Susanne K Kjaer; Douglas A Levine; Jacek Gronwald; Hoda Anton Culver; Alice S Whittemore; Beth Y Karlan; Diether Lambrechts; Nicolas Wentzensen; Jolanta Kupryjanczyk; Jenny Chang-Claude; Elisa V Bandera; Estrid Hogdall; Florian Heitz; Stanley B Kaye; Peter A Fasching; Ian Campbell; Marc T Goodman; Tanja Pejovic; Yukie T Bean; Laura E Hays; Galina Lurie; Diana Eccles; Alexander Hein; Matthias W Beckmann; Arif B Ekici; James Paul; Robert Brown; James M Flanagan; Philipp Harter; Andreas du Bois; Ira Schwaab; Claus K Hogdall; Lene Lundvall; Sara H Olson; Irene Orlow; Lisa E Paddock; Anja Rudolph; Ursula Eilber; Agnieszka Dansonka-Mieszkowska; Iwona K Rzepecka; Izabela Ziolkowska-Seta; Louise A Brinton; Hannah Yang; Montserrat Garcia-Closas; Evelyn Despierre; Sandrina Lambrechts; Ignace Vergote; Christine S Walsh; Jenny Lester; Weiva Sieh; Valerie McGuire; Joseph H Rothstein; Argyrios Ziogas; Jan Lubiński; Cezary Cybulski; Janusz Menkiszak; Allan Jensen; Simon A Gayther; Susan J Ramus; Aleksandra Gentry-Maharaj; Andrew Berchuck; Anna H Wu; Malcolm C Pike; David Van Den Berg; Kathryn L Terry; Allison F Vitonis; Starr M Ramirez; David N Rider; Keith L Knutson; Thomas A Sellers; Catherine M Phelan; Jennifer A Doherty; Sharon E Johnatty; Anna deFazio; Honglin Song; Jonathan Tyrer; Kimberly R Kalli; Brooke L Fridley; Julie M Cunningham; Ellen L Goode
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-04-16       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.